VBI Vaccines (OTCPK:VBIV.Q) - Aktienkurs, Nachrichten und Analyse

VBIV.Q Aktienübersicht

VBI Vaccines Inc., ein biopharmazeutisches Unternehmen im kommerziellen Stadium, entwickelt und vertreibt Impfstoffe zur Behandlung von Immunonkologie und Infektionskrankheiten. Mehr Details

VBIV.Q grundlegende Analyse
Schneeflocken-Punktzahl
Bewertung	2/6
Künftiges Wachstum	0/6
Vergangene Leistung	0/6
Finanzielle Gesundheit	2/6
Dividenden	0/6

Risikoanalyse

Hat keine nennenswerte Marktkapitalisierung ($14K)

Negatives Eigenkapital

Die Erträge sind in den letzten 5 Jahren um 17.4% pro Jahr zurückgegangen

Stark schwankender Aktienkurs in den letzten 3 Monaten

+ 1 mehr Risiko

VBI Vaccines Inc. Wettbewerber

Aditxt

NasdaqCM:ADTX

US$2.8m

TRACON Pharmaceuticals

OTCPK:TCON

US$100.5k

Genocea Biosciences

OTCPK:GNCA.Q

US$5.9k

Aridis Pharmaceuticals

OTCPK:ARDS

US$53.0

Preisentwicklung & Leistung

Übersicht über alle Höchststände, Veränderungen und Kursrückgänge für VBI Vaccines
Historische Aktienkurse
Aktueller Aktienkurs	US$0.0005
52-Wochen-Hoch	US$1.35
52-Wochen-Tief	US$0.0002
Beta	2.22
11 Monat Veränderung	0%
3 Monate Veränderung	-97.37%
1 Jahr Veränderung	-99.92%
33 Jahre Veränderung	-100.00%
5 Jahre Veränderung	-100.00%
Veränderung seit IPO	-100.00%

Aktuelle Nachrichten und Updates

Recent updates

VBI Vaccines down 10% on $300M mixed shelf offering; also ends two equity offerings

Aug 26

VBI Vaccines: Recent VBI-1901 Data Supports My Bull Thesis

Jun 17

Is VBI Vaccines (NASDAQ:VBIV) A Risky Investment?

Jun 09

Is VBI Vaccines (NASDAQ:VBIV) Using Debt Sensibly?

Jan 24

Aktionärsrenditen

	VBIV.Q	US Biotechs	US Markt
7D	0%	2.4%	2.2%
1Y	-99.9%	16.2%	31.7%

Rendite im Vergleich zur Industrie: VBIV.Q unter dem Niveau der Branche US Biotechs , die im vergangenen Jahr eine Rendite von 16.2% erzielte.

Rendite vs. Markt: VBIV.Q hinter dem Markt US zurück, der im vergangenen Jahr eine Rendite von 31.7 erzielte.

Preisvolatilität

Is VBIV.Q's price volatile compared to industry and market?
VBIV.Q volatility
VBIV.Q Average Weekly Movement	52.0%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.8%
10% least volatile stocks in US Market	3.1%

Stabiler Aktienkurs: VBIV.QDer Aktienkurs des Unternehmens war in den letzten 3 Monaten unbeständig.

Volatilität im Zeitverlauf: VBIV.QDie wöchentliche Volatilität der Aktie ist im vergangenen Jahr von 36% auf 52% gestiegen.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
n/a	135	Jeff Baxter	www.vbivaccines.com

VBI Vaccines Inc. ist ein biopharmazeutisches Unternehmen im kommerziellen Stadium, das Impfstoffe zur Behandlung von Immunonkologie und Infektionskrankheiten entwickelt und vertreibt. Es bietet Impfstoffe gegen Hepatitis B (HBV) unter den Markennamen PreHevbrio, PreHevbri und Sci-B-Vac an. Das Unternehmen entwickelt außerdem VBI-2601, einen proteinbasierten immuntherapeutischen Kandidaten zur Behandlung chronischer HBV-Infektionen; VBI-1901, einen immuntherapeutischen Impfstoffkandidaten gegen Glioblastom-Krebs; VBI-1501, einen prophylaktischen Impfstoffkandidaten gegen das Zytomegalievirus; und VBI-2501 zur Behandlung des Zika-Virus.

VBI Vaccines Inc.'s Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von VBI Vaccines im Vergleich zum Marktanteil des Unternehmens?
VBIV.Q grundlegende Statistiken
Marktanteil	US$14.34k
Gewinn(TTM)	-US$83.99m
Umsatz(TTM)	US$9.41m

0.0x

Kurs-Umsatz-Verhältnis

0.0x

Kurs-Gewinn-Verhältnis

Ist VBIV.Q zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
VBIV.Q Gewinn- und Verlustrechnung (TTM)
Einnahmen	US$9.41m
Kosten der Einnahmen	US$11.67m
Bruttogewinn	-US$2.26m
Sonstige Ausgaben	US$81.73m
Umsatz	-US$83.99m

Zuletzt gemeldete Gewinne

Mar 31, 2024

Datum des nächsten Gewinnberichts

k.A.

Gewinn per Aktie (EPS)	-2.93
Bruttomarge	-24.03%
Nettogewinnspanne	-892.47%
Schulden/Eigenkapital-Verhältnis	-891.6%

Wie hat sich VBIV.Q auf lange Sicht entwickelt?

Historische Performance und Vergleiche

VBIV.Q Aktienübersicht

Risikoanalyse

VBI Vaccines Inc. Wettbewerber

NasdaqCM:ADTX

US$2.8m

OTCPK:TCON

US$100.5k

OTCPK:GNCA.Q

US$5.9k

OTCPK:ARDS

US$53.0

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

VBI Vaccines Inc. Issues Voluntary Nationwide Recall of All PreHevbrio Vaccine Due to Discontinuation of Company Operations

The Nasdaq Stock Market to Delist Ordinary Shares of VBI Vaccines

VBI Vaccines Inc.(OTCPK:VBIV.Q) dropped from NASDAQ Composite Index

Nasdaq Determines to Delist Common Stock of VBI Vaccines in Accordance with Listing Rules 5101, 5110(b), and IM-5101-1

Nasdaq Provides Until July 8 Deadline to VBI Vaccines to Meet Minimum Stockholders' Equity Requirement

VBI Vaccines Inc. Announces Poster Presentation at 2024 ASCO Annual Meeting Highlighting New Interim Phase 2b Data from VBI-1901 in Recurrent Glioblastoma Patients

Recent updates

VBI Vaccines Inc. Issues Voluntary Nationwide Recall of All PreHevbrio Vaccine Due to Discontinuation of Company Operations

The Nasdaq Stock Market to Delist Ordinary Shares of VBI Vaccines

VBI Vaccines Inc.(OTCPK:VBIV.Q) dropped from NASDAQ Composite Index

Nasdaq Determines to Delist Common Stock of VBI Vaccines in Accordance with Listing Rules 5101, 5110(b), and IM-5101-1

Nasdaq Provides Until July 8 Deadline to VBI Vaccines to Meet Minimum Stockholders' Equity Requirement

VBI Vaccines Inc. Announces Poster Presentation at 2024 ASCO Annual Meeting Highlighting New Interim Phase 2b Data from VBI-1901 in Recurrent Glioblastoma Patients

VBI Vaccines Inc. has filed a Follow-on Equity Offering in the amount of $8.468289 million.

VBI Vaccines Inc. has completed a Follow-on Equity Offering in the amount of $2.000001 million.

VBI Vaccines Inc. has filed a Follow-on Equity Offering in the amount of $2.000001 million.

VBI Vaccines Inc. Presents Encouraging Early Tumor Response Data from Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma

VBI Vaccines Inc. announced delayed annual 10-K filing

VBI Vaccines Inc. Presents Additional Biomarker Data from Phase 1/2a Study of VBI-1901 in Recurrent GBM at the 2023 Society for Neuro-Oncology Annual Meeting

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

VBI Vaccines Inc. Receives a Letter from the Listing Qualifications Department of the Nasdaq Stock Market

VBI Vaccines Expands Proprietary Technology Platforms With Development of a Novel mRNA-Launched eVLP Vaccine Program

VBI Vaccines Inc. Announces Interim Data from the Phase 1 Clinical Study of its Multivalent Pan-Coronavirus Vaccine Candidate, VBI-2901

VBI Vaccines Inc. Announces Dosing of First Patients in Phase 2b Study of VBI-1901 in Recurrent GBM

Consensus revenue estimates increase by 291%, EPS downgraded

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

VBI Vaccines Inc. Announces PreHevbri® is Now Available in the Netherlands and Belgium for the Prevention of Hepatitis B in Adults

Consensus EPS estimates upgraded to US$4.46 loss

New major risk - Shareholder dilution

VBI Vaccines Inc. has completed a Follow-on Equity Offering in the amount of $18 million.

VBI Vaccines Inc. announced that it expects to receive $3 million in funding from Brii Biosciences Limited

VBI Vaccines Inc.(NasdaqCM:VBIV) dropped from Russell 2000 Dynamic Index

VBI Vaccines Inc. Announces Prehevbri® Is Now Available in the United Kingdom for the Prevention of Hepatitis B in Adults

Now 21% undervalued after recent price drop

Consensus revenue estimates decrease by 38%, EPS upgraded

Price target decreased by 45% to US$33.00

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates fall by 1,377%

Insufficient new directors

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

No longer forecast to breakeven

VBI Vaccines Announces Presentation of Interim Phase 2 Data Evaluating Combination of VBI-2601 (BRII-179) and BRII-835 for the Treatment of Chronic Hepatitis B

VBI Vaccines Inc. Announces Health Canada Approval for Prehevbrio™ for Prevention of Hepatitis B in Adults

No longer forecast to breakeven

VBI Vaccines Presents Additional Phase 1/2A Data from VBI-1901 in Recurrent GBM At the 2022 Society for Neuro-Oncology Annual Meeting

Consensus forecasts updated

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

VBI Vaccines Announces Initiation of Phase 1 Study of Multivalent Coronavirus Vaccine Candidate, VBI-2901

VBI Vaccines: Recent Updates Have Fortified My Long-Term Outlook

VBI Vaccines Inc. Announces Presentation of Physician-Initiated Compassionate Use Data of Its 3-Antigen Hepatitis B Vaccine At the 2022 International HBV Meeting

VBI Vaccines gets up to $100M debt funding from K2 HealthVentures

VBI Vaccines Inc. Announces the Resignation of Linda C. Bain from the Board of Directors

Valneva, VBI Vaccines in pact to launch Hep B vaccine in Europe

VBI Vaccines down 10% on $300M mixed shelf offering; also ends two equity offerings

Consensus revenue estimates fall by 32%

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

VBI Vaccines Inc. Announces Appointment of John Dillman as Chief Commercial Officer

VBI Vaccines Receives Non-Compliance Notice from Nasdaq

VBI Vaccines Announces New Long-Term Follow-Up Clinical Data for Its 3-Antigen Adult Hepatitis B Vaccine

VBI Vaccines Inc. Receives U.S. Food and Drug Administration Orphan Drug Designation for VBI-1901 for the Treatment of Glioblastoma

VBI Vaccines: Recent VBI-1901 Data Supports My Bull Thesis

Is VBI Vaccines (NASDAQ:VBIV) A Risky Investment?

VBI Vaccines Inc. Announces Updated Phase 2A Tumor Response and Overall Survival Data for VBI-1901

VBI Vaccines Inc. Announces UK MHRA Marketing Authorisation for Prehevbri

Consensus forecasts updated

First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Erträge & Einnahmen